Marshall Edwards, an oncology company, has hired industry veteran Thomas Zech as chief financial officer, less than two months after appointing Daniel Gold as chief executive officer (CEO).
Zech joins Marshall Edwards with more than 35 years of experience in finance and accounting, including over 20 years in the life science industry. He replaces departing CFO David Seaton, who also served as acting CEO from December 2009 until the appointment of Gold in April 2010.
Most recently, Zech served as vice president, finance and CFO at Pacira Pharmaceuticals, a specialty pharmaceutical company founded in 2007 through the acquisition of the former SkyePharma injectable business. He transitioned to Pacira Pharmaceuticals from SkyePharma, where he joined in 1999 as controller and corporate secretary. Previously he held senior finance positions at Stratagene, Advanced Tissue Sciences, Allied Holdings and Psicor. Zech earned his bachelor’s degree in accounting from Lawrence Technological University and his master’s degree in finance from the University of Detroit.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.